flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 Get With the FLOW! in: News Volume 16 Issue 8 (2024) Kidney Outcomes With Glucagon-Like Peptide-1

Cai, Brian Toy, Benjamin Martin, Ruochong Fan, Erik Westlund, Diep Tran, Akihiko Nishimura, Haeun Lee, Theodore Leng, Paul Nagy, Nestoras Mathioudakis, Linying Zhang, Michelle Hribar, Aiyin Chen, Karen Armbrust, Kerry Goetz, Sally Baxter, Michael V

T-REX trial: GLP-1 agonist with structured resistance training

How much weight can you lose on oral semaglutide

Migraine relief: a promising emerging benefit Migraine affects women at roughly three times the rate of men and it is one of the most undertreated conditions in womens health

This review synthesizes current preclinical and clinical evidence on the molecular and cellular mechanisms through which semaglutide modulates adipose tissue biology in T2DM

Its primary mechanism of action involves stimulating specific receptors on the pituitary gland, triggering the release of human growth hormone (HGH) into the bloodstream (1)